License agreement additional Milestone payment.

No definition available.

Name:	oric_LicenseAgreementAdditionalMilestonePayment
Namespace Prefix:	oric_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

License agreement cash payment related to acquired assets charge.

+ References

No definition available.

+ Details

Name:	oric_LicenseAgreementCashPaymentRelatedToAcquiredAssetsCharge
Namespace Prefix:	oric_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

License agreement charge related to acquired assets.

+ References

No definition available.

+ Details

Name:	oric_LicenseAgreementChargeRelatedToAcquiredAssets
Namespace Prefix:	oric_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

License agreement maximum milestone payment obligation to pay.

+ References

No definition available.

+ Details

Name:	oric_LicenseAgreementMaximumMilestonePaymentObligationToPay
Namespace Prefix:	oric_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

License agreement shares issued value related to acquired assets charge.

+ References

No definition available.

+ Details

Name:	oric_LicenseAgreementSharesIssuedValueRelatedToAcquiredAssetsCharge
Namespace Prefix:	oric_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

License agreements.

+ References

No definition available.

+ Details

Name:	oric_LicenseAgreementsLineItems
Namespace Prefix:	oric_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of licensed products obliged to develop and commercialize.

+ References

No definition available.

+ Details

Name:	oric_NumberOfLicensedProductsObligedToDevelopAndCommercialize
Namespace Prefix:	oric_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of period the agreement in effect.

+ References

No definition available.

+ Details

Name:	oric_NumberOfPeriodAgreementInEffect
Namespace Prefix:	oric_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Shares issued percentage of premium.

+ References

No definition available.

+ Details

Name:	oric_SharesIssuedPercentageOfPremium
Namespace Prefix:	oric_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Stock transfer restrictions period.

+ References

No definition available.

+ Details

Name:	oric_StockTransferRestrictionsPeriod
Namespace Prefix:	oric_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Upfront cash payment.

+ References

No definition available.

+ Details

Name:	oric_UpfrontCashPayment
Namespace Prefix:	oric_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_CommonStockSharesIssued
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

+ Details

Name:	us-gaap_CommonStockValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Per share or per unit amount of equity securities issued.

+ References

No definition available.

+ Details

Name:	us-gaap_SharesIssuedPricePerShare
Namespace Prefix:	us-gaap_
Data Type:	num:perShareItemType
Balance Type:	na
Period Type:	instant

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=oric_MiratiTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=oric_AcquiredInProcessResearchAndDevelopmentExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=oric_VoronoiIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=oric_DevelopmentAndRegulatoryMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=oric_CommercialMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=oric_SuccessBasedMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

License Agreements - Additional Information (Details) $ / shares in Units, $ in Thousands			1 Months Ended
	Oct. 19, 2020 USD ($) Product $ / shares shares	Aug. 03, 2020 USD ($) Product $ / shares shares	Oct. 31, 2020 USD ($)	Aug. 31, 2020 USD ($)	Jun. 30, 2021 USD ($) shares	Dec. 31, 2020 USD ($) shares
License Agreements [Line Items]
Number of licensed products obliged to develop and commercialize \| Product	1	1
Upfront payment shares issued \| shares					36,715,612	36,672,415
Upfront payment value					$ 4	$ 4
Mirati Therapeutics, Inc
License Agreements [Line Items]
Number of period the agreement in effect		10 years
Mirati Therapeutics, Inc \| Private Placement \| Acquired In-Process Research and Development Expense
License Agreements [Line Items]
License agreement shares issued value related to acquired assets charge				$ 13,000
Mirati Therapeutics, Inc \| Private Placement \| Common Stock
License Agreements [Line Items]
Upfront payment shares issued \| shares		588,235
Upfront payment value		$ 13,000
Issue price per share \| $ / shares		$ 34.00
Premium percentage		10.00%
Stock transfer restrictions period		18 months
Voronoi Inc. \| Development And Regulatory Milestone
License Agreements [Line Items]
License agreement maximum milestone payment obligation to pay	$ 111,000
Voronoi Inc. \| Commercial Milestone
License Agreements [Line Items]
License agreement maximum milestone payment obligation to pay	225,000
Voronoi Inc. \| Success Based Milestones
License Agreements [Line Items]
License agreement, additional milestone payment	$ 272,000
Voronoi Inc. \| Private Placement
License Agreements [Line Items]
License agreement charge related to acquired assets			$ 11,800
Voronoi Inc. \| Private Placement \| Acquired In-Process Research and Development Expense
License Agreements [Line Items]
License agreement shares issued value related to acquired assets charge			6,800
License agreement cash payment related to acquired assets charge			$ 5,000
Voronoi Inc. \| Private Placement \| Common Stock
License Agreements [Line Items]
Upfront payment shares issued \| shares	283,259
Upfront payment value	$ 6,800
Issue price per share \| $ / shares	$ 28.24
Premium percentage	25.00%
Upfront cash payment	$ 5,000